NoGeneST™ Anti-Factor IXa Aptamer, aFIXa aptamer-1 sodium

Name: NoGeneST™ Anti-Factor IXa Aptamer, aFIXa aptamer-1 sodium
SKU: NRYF-0625-HZ9
Rating: 5 (1 reviews)

[CAT#: NRYF-0625-HZ9]

Inhibits tissue factor pathway inhibitor (TFPI)

Target:: FIXa

Type:: RNA

Datasheet MSDS Request COA

Certificate of Analysis Lookup
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number

Inquiry

Product Overview

Description

This profile represents a pegylated oligonucleotide aptamer developed for targeted anticoagulation. The molecule consists of a high-affinity synthetic nucleic acid sequence linked to a polyethylene glycol (PEG) moiety, which significantly extends its circulatory half-life and optimizes its therapeutic index. The core function of this agent is to bind and neutralize Factor XIa, a critical serine protease in the amplification loop of the coagulation cascade. By selectively inhibiting FXIa, the aptamer effectively decouples pathological thrombus propagation from essential hemostasis, presenting a paradigm shift in anticoagulant therapy toward a safer and more predictable clinical outcome.

Type

RNA

Properties

Size

1 mg; 5 mg; 10 mg

Appearance

Supplied as a lyophilized white to off-white solid.

Purity

>90%

Shipping

Room temperature

Storage

Powder Form: Stable for 3 years when stored at -20°C.
In Solvent: Stable for 6 months when aliquoted and stored at -80°C

Research Use Only

For Research Use Only

Target Details

Target

FIXa

Full Name

Fator IXa

Alternative Names

Coagulation Factor IXa; Christmas factor; Plasma thromboplastin component (PTC)

Gene ID

2158

Uniprot ID

P000740

Target Overview

Coagulation Factor IX (FIX) is a vitamin K-dependent serine protease that plays a crucial role in the intrinsic pathway of blood coagulation. It circulates in the blood as an inactive zymogen. Upon activation to Factor IXa (FIXa), it complexes with its cofactor, Factor VIIIa, to activate Factor X. This step is essential for amplifying the generation of thrombin and forming a stable blood clot. Genetic deficiency of Factor IX leads to the bleeding disorder hemophilia B, highlighting its importance in hemostasis.

Publications